Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its price target trimmed by Citigroup from $27.00 to $26.00 in a ...

Q4 2024 Earnings Call Transcript November 26, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Algert Global LLC reduced its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 8.6% in ...

Arrowhead Pharmaceuticals, Inc. (ARWR) has disclosed a new risk, in the Sales & Marketing category. The reliance of Arrowhead ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Goldman has recently initiated Arrowhead Pharmaceuticals Inc (ARWR) stock to Neutral rating, as announced on June 5, 2024, according to Finviz. Earlier, on December 4, 2023, BofA Securities had ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Arrowhead Pharmaceuticals, Inc. ( (ARWR) ) has released its Q4 earnings. Here is a breakdown of the information Arrowhead Pharmaceuticals, Inc.

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target ...

Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET. Company Participants. Vince Anzalone - VP, IR Chris Anzalone - Preside ...

Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...